VYNE Therapeutics Inc.
VYNE
$0.59
$0.000.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 130.00K | 169.00K | 69.00K | 202.00K | 84.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 130.00K | 169.00K | 69.00K | 202.00K | 84.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 130.00K | 169.00K | 69.00K | 202.00K | 84.00K |
| SG&A Expenses | 2.37M | 2.71M | 2.73M | 3.28M | 3.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.35M | 7.96M | 7.61M | 9.40M | 12.85M |
| Operating Income | -5.22M | -7.79M | -7.54M | -9.20M | -12.77M |
| Income Before Tax | -4.96M | -7.43M | -5.75M | -8.60M | -12.01M |
| Income Tax Expenses | 4.00K | -- | -- | -- | 4.00K |
| Earnings from Continuing Operations | -4.96M | -7.43M | -5.75M | -8.60M | -12.01M |
| Earnings from Discontinued Operations | 123.00K | 146.00K | -8.00K | -8.00K | -8.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.84M | -7.28M | -5.76M | -8.61M | -12.02M |
| EBIT | -5.22M | -7.79M | -7.54M | -9.20M | -12.77M |
| EBITDA | -5.21M | -7.79M | -7.54M | -9.19M | -12.77M |
| EPS Basic | -0.11 | -0.17 | -0.13 | -0.20 | -0.28 |
| Normalized Basic EPS | -0.07 | -0.11 | -0.10 | -0.13 | -0.18 |
| EPS Diluted | -0.11 | -0.17 | -0.13 | -0.20 | -0.28 |
| Normalized Diluted EPS | -0.07 | -0.11 | -0.10 | -0.13 | -0.18 |
| Average Basic Shares Outstanding | 42.84M | 42.80M | 42.76M | 42.67M | 42.60M |
| Average Diluted Shares Outstanding | 42.84M | 42.80M | 42.76M | 42.67M | 42.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |